Carboplatino Hikma 10 mg/ml soluzione per infusione
Sponsors
Azienda Provinciale Per I Servizi Sanitari, Centro Di Riferimento Oncologico Di Aviano, Glaxosmithkline Research & Development Limited, Glaxosmithkline Research & Development Limited, Fondazione Ricerca Traslazionale, Oncomatryx Biopharma S.L.
Conditions
ALK positive Non-Small Cell Lung CancerAdvanced/Metastatic Non-squamous Non-Small Cell Lung CancerGynecologicalTumoursprostate cancerstage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)
Phase 1
A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors.
RecruitingCTIS2024-517147-31-00
Start: 2025-05-23Target: 217Updated: 2025-11-24
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
Not yet recruitingCTIS2025-521989-95-00
Target: 88Updated: 2025-12-12
Phase 2
A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based chemotherapy plus Lorlatinib in ALK positive Non-Small Cell Lung Cancer (NSCLC) with exclusively extracranial disease progression on Lorlatinib
RecruitingCTIS2023-506714-43-00
Start: 2024-03-15Target: 45Updated: 2025-10-21
Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts
Not yet recruitingCTIS2023-503676-25-01
Target: 157Updated: 2024-11-18
Neoadjuvant chemo-immunotherapy for stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)
RecruitingCTIS2024-519205-35-01
Start: 2025-07-08Target: 30Updated: 2025-09-10